Free and total lipid myo-inositol concentrations decrease with age in human brain.

C. Stokes,K. Gillon,J. Hawthorne

DOI: https://doi.org/10.1016/0005-2760(83)90108-X

1983-08-29

Biochimica et Biophysica Acta

Abstract:

What problem does this paper attempt to address?

Case report: A novel compound heterozygous variant in the COL4A3 gene was identified in a patient with autosomal recessive Alport syndrome

Sha Chen,Yufeng Zhang,Jinjin He,Dingwei Yang

DOI: https://doi.org/10.3389/fgene.2024.1426806

IF: 3.7

2024-07-13

Frontiers in Genetics

Abstract:Alport syndrome (AS), a hereditary kidney disease with a high risk for renal failure, is attributed to pathogenic variants in genes COL4A3 , COL4A4 , and COL4A5 that encode type IV collagen. Next-generation sequencing (NGS) is increasingly applied to the diagnosis of AS, but complex genotype–phenotype correlation, that is, identifying the significance of variants, is still a huge clinical challenge. In this study, we reported the case of a 27-year-old Chinese woman with a family history of hematuria and proteinuria. Notably, the proband is the only one in her family with renal insufficiency. NGS was performed in this family, and it was revealed that the proband was a compound heterozygote for two variants in the COL4A3 gene: c.2990G>A inherited from her father and c.4981C>T inherited from her mother. We modeled the spatial structure of the corresponding protein and assumed that structural abnormalities led to the breakdown of type IV collagen networks, a major component of the glomerular basement membrane. Thus, the proband was diagnosed with autosomal recessive AS, characterized by severe defects of the glomerular basement membrane. Hence, the proband showed a loss of renal function. This case presentation emphasizes the importance of NGS for AS diagnosis and introduces a novel genotype of AS.

genetics & heredity
Novel Digenic Variants in COL4A4 and COL4A5 Causing X-Linked Alport Syndrome: A Case Report

Hideki Uedono,Katsuhito Mori,Shinya Nakatani,Kohei Watanabe,Rino Nakaya,Fumiyuki Morioka,Kazuma Sone,Chie Ono,Junko Hotta,Akihiro Tsuda,Naoya Morisada,Toshiyuki Seto,Kandai Nozu,Masanori Emoto

DOI: https://doi.org/10.1159/000535493

2024-01-03

Abstract:Introduction: Alport syndrome (AS) is a hereditary, progressive kidney disease characterized by structural abnormalities and dysfunction of the glomerular basement membrane (GBM). AS is classified as X-linked, autosomal, and digenic. The number of cases of digenic AS has increased, but the genotype-phenotype correlation of patient with digenic AS is still unclear. Here, we present a case of digenic AS with novel digenic missense variants in COL4A4 (c.827G>C, p.Gly276Ala) and COL4A5 (c.4369G>C, p.Gly1457Arg). Case presentation: The patient was a 29-year-old Japanese man suffering from persistent microscopic hematuria and proteinuria without kidney function impairment. Kidney biopsy showed focal interstitial foam cell infiltration, global and segmental glomerulosclerosis. Immunofluorescence staining for collagen IV α5 was almost negative in the GBM and Bowman's capsule. Electron microscopy revealed irregular thickening with lamellation and segmental thinning of the GBM. Clinical and pathological findings were consistent with AS. Comprehensive next-generation sequencing revealed a heterozygous missense variant in COL4A4 (c.827G>C, p.Gly276Ala) in exon 1 and a hemizygous missense variant in COL4A5 (c.4369G>C, p.Gly1457Arg) in exon 49 on the patient's paternal and maternal alleles, respectively. The same digenic variants were detected in his sister, and she also showed a similar phenotype. After treatment with angiotensin-converting enzyme inhibitors, proteinuria decreased from 2.3 to 1.1 g/g creatinine, but occult blood persisted. During follow-up, kidney function has been preserved. Conclusion: The novel genotype of our case provides more information on the genotype-phenotype correlation of digenic XLAS, although long-term follow-up is required. The findings in the present case also indicate the importance of genetic tests for family members of a patient diagnosed with digenic AS.
Identification of a Novel COL4A5 Mutation in the Proband Initially Diagnosed As IgAN from a Chinese Family with X-linked Alport Syndrome.

Zhihui Li,Peng Zhu,Hui Huang,Ying Pan,Peng Han,Huanhuan Cui,Zhijuan Kang,Mai Xun,Yi Zhang,Saijun Liu,Jian Wang,Jing Wu

DOI: https://doi.org/10.1007/s11427-018-9545-3

2019-01-01

Science China Life Sciences

Abstract:Alport syndrome (AS) is a hereditary progressive nephropathy characterized by hematuria, ultrastructural lesions of the glomerular basement membrane, ocular lesions and sensorineural hearing loss. Germline mutations of COL4A5 are associated with X-linked AS with an extreme phenotypic heterogeneity. Here, we investigated a Chinese family with Alport syndrome. The proband was a 9-year-old boy with hematuria and proteinuria. Based on the test results of renal biopsy and immunofluorescence, the proband was initially diagnosed as IgA nephropathy and the treatment was recommended accordingly. Meanwhile, we found that the treatment outcome was poor. Therefore, for proper clinical diagnosis and appropriate treatment, targeted exome-based next-generation sequencing has been undertaken. We identified a novel hemizygous single nucleotide deletion c.1902delA in COL4A5 gene. Segregation analysis identified that this novel mutation is co-segregated among the affected family members but absent in unaffected family members. The clinical diagnosis of the proband was revised as AS accompanied by IgA nephropathy, which has been rarely reported. Our findings demonstrated the significance of the application of Genetic screening, expanded the mutation spectrum of COL4A5 associated AS patients with atypical renal phenotypes and provided a good lesson to be learned from our detour during the diagnosis.
A Novel COL4A5 Pathogenic Variant Joins the Dots in a Family with a Synchronous Diagnosis of Alport Syndrome and Polycystic Kidney Disease

Ludovico Graziani,Chiara Minotti,Miriam Lucia Carriero,Mario Bengala,Silvia Lai,Alessandra Terracciano,Antonio Novelli,Giuseppe Novelli

DOI: https://doi.org/10.3390/genes15050597

IF: 4.141

2024-05-08

Genes

Abstract:Alport Syndrome (AS) is the most common genetic glomerular disease, and it is caused by COL4A3, COL4A4, and COL4A5 pathogenic variants. The classic phenotypic spectrum associated with AS ranges from isolated hematuria to chronic kidney disease (CKD) with extrarenal abnormalities. Atypical presentation of the disorder is possible, and it can mislead the diagnosis. Polycystic kidney disease (PKD), which is most frequently associated with Autosomal Dominant PKD (ADPKD) due to PKD1 and PKD2 heterozygous variants, is emerging as a possible clinical manifestation in COL4A3-A5 patients. We describe a COL4A5 novel familial frameshift variant (NM_000495.5: c.1095dup p.(Leu366ValfsTer45)), which was associated with AS and PKD in the hemizygous proband, as well as with PKD, IgA glomerulonephritis and focal segmental glomerulosclerosis (FSGS) in the heterozygous mother. Establishing the diagnosis of AS can sometimes be difficult, especially in the context of misleading family history and atypical phenotypic features. This case study supports the emerging genotypic and phenotypic heterogeneity in COL4A3-A5-associated disorders, as well as the recently described association between PKD and collagen type IV (Col4) defects. We highlight the importance of the accurate phenotyping of all family members and the relevance of next-generation sequencing in the differential diagnosis of hereditary kidney disease.

genetics & heredity
A Novel Mutation of COL4A3 Presents a Different Contribution to Alport Syndrome and Thin Basement Membrane Nephropathy

Ping Hou,Yuqing Chen,Jiaxiang Ding,Guangtao Li,Hong Zhang

DOI: https://doi.org/10.1159/000107666

2007-01-01

American Journal of Nephrology

Abstract:Background: Alport syndrome (AS) and thin basement membrane nephropathy (TBMN) are heterogeneous renal hereditary diseases. Mutations of COL4A3 and COL4A4 genes were reported to be the underlying pathogenicity in both diseases. However, the mechanism of the same mutation causing totally different clinical processes and outcomes in AS and TBMN is still not clear. Subjects and Methods: Mutations of all coding exons of COL4A3 and COL4A4 were screened in a patient with autosomal recessive Alport syndrome (ARAS) of a Chinese Han consanguineous family by means of PCR and direct sequencing. Furthermore, the identified mutation was validated by restriction endonuclease AvaII in all 20 members in his family, as well as 46 patients with TBMN, 2 patients with AS from another two families, and 50 healthy controls. Results: A novel missense mutation (3725G>A, G1242D) in exon 42 of COL4A3 was identified in the proband in the homozygous form. This pathogenic mutation was demonstrated in all carriers who presented with hematuria or mild proteinuria in the heterozygous form, whereas it was not detected in others whose urinalysis was normal within the family. In addition, 10 polymorphisms, including 1 non-glycine missense variant and 9 neutral polymorphisms, were detected in COL4A3/COL4A4. Conclusion: The novel mutation (3725G>A, G1242D) of COL4A3 was the underlying pathogenic role in the homozygous form in ARAS and in the heterozygous form in TBMN within an identical family. The result provided a potentially useful clue for the functional investigation of COL4A3 in these two hereditary glomerular disorders.
Autosomal Dominant Alport Syndrome Caused by a Novel COL4A4 Gene Mutation:a Case Report and Literature Review

GUO Ting,ZHANG Jian,DING Ying,YANG Xiaoqing,ZHAI Wensheng,SONG Chundong,ZHANG Xia,ZHANG Bo,GAO Xuguang,LIU Liya

DOI: https://doi.org/10.12114/j.issn.1007-9572.2022.0528

2023-01-01

Chinese General Practice

Abstract:Alport syndrome (AS) is one of the important causes of chronic kidney disease and end-stage renal disease. It is the second most common inherited kidney disease after autosomal dominant polycystic kidney disease. Autosomal dominant inheritance is a very rare mode of inheritance in AS, and patients with autosomal dominant forms of AS (ADAS) were previously reported to progress to end-stage renal disease at a later age. This article reported a patient who was diagnosed with ADAS in the Pediatric Nephrology Department of the First Affiliated Hospital of Henan University of CM on September 5, 2019 because of abnormal urine test findings for 4 years. The clinical data and genetic test results were reviewed. We reported the clinical, renal pathology and gene mutation of a ADAS family caused by the new mutation c.3506-3528del (p.G1169Efs*13) of COL4A4 gene (One family member developed end-stage renal disease at the age of 31). We also summarized the literature reports of Chinese ADAS, and made a comprehensive analysis of the relationship between the gene, clinical phenotype and prognosis of the disease. Due to the low incidence of ADAS, this family report expands the gene mutation spectrum of AS, and helps to improve clinicians' awareness and timely diagnosis and treatment of rare-onset ADAS.
Lithium, clinical research, and cystic fibrosis

T. Boat

DOI: https://doi.org/10.1002/ppul.1950080203

IF: 4.0899

Pediatric Pulmonology

Abstract:The cellular defect responsible for the cystic fibrosis (CF) syndrome has eluded precise description, although a flurry of reports over the past 6-7 years has identified the cell sites and the general nature of the dysfunction. Most likely, structural abnormalities of a membrane-associated regulatory protein' result in an inability to upregulate chloride channels and down-regulate sodium channels in the apical membranes of epithelial cells including those of conducting airways. * The postulated consequence in the lung is a net movement of salt and water from surface liquids into airway tissues, making mucous secretions salt deficient, relatively dehydrated, and refractory to clearance by ciliary mechanisms or cough.3 Intracellular regulation of ion translocation involves protein kinase A, protein kinase C, and intracellular calcium. The first two are ineffective modulators in CF epithelial cells ,4-8 but elevation of intracellular calcium does appear to open chloride channels in CF cells. With this information in hand, it is not surprising that thoughts are turning to the identification of more specific pharmacologic interventions for CF patients. Anbar and associates' in this issue cite previous work indicating that lithium may affect calcium metabolism" and the function of G proteins,'' several of which are involved with cation-channel regulation. l 2 They speculated that lithium might effect beneficial changes in CF epithelial function and undertook a double-blind, placebo-controlled trial of this drug in older CF patients. While such investigative approaches are to be encouraged, a more usual sequence of scientific inquiry would have been to first test the effect of lithium on ion translocation in cultured CF epithelial cells, thereby developing a stronger rationale for the clinical study. Had this been done, a rather extensive clinical trial that placed patients at some risk of adverse reactions and that had a largely negative outcome might not have been initiated. On the other hand, under these circumstances the authors would not have contributed the observation that lithium may be a risky drug for individuals with CF. This observation is likely to be a practical one, in that as the CF population ages, more and more patients with bipolar disorders needing lithium treatment are likely to be encountered. The observation by Anbar and colleagues that concentrations of chloride in sweat diminish during lithium treatment of individuals with CF is eye catching, but at second glance is neither physiologically impressive nor clearly indicative of a lithium effect on ion translocation mechanisms in sweat duct cells. Lithium could have achieved this effect by, for example, altering the rate of sweat production, a factor known to influence its chloride concentrations. l3 Furthermore, the importance of a small decrease in mean sweat chloride concentrations between preand post-treatment samples in this study is obscured by the recognition that 6 of 18 CF sweat chloride values were unchanged or increased after lithium administration. Although more than twice the number of hospitalizations were required for lithium-treated patients during and within 19 weeks after its administration, it is not certain that this effect was entirely attributable to declining pulmonary function. One complicating factor is that the two groups of subjects were not comparable on entry into the study. Patients to be treated with lithium had better mean FVC and FEV, values by more than 10% and 20%, respectively. Furthermore the small declines in these parameters were maximal at 4 weeks of lithium treatment, and by 10 weeks mean values had moved closer to entry levels. Thus, it is not clear that the increased need for hospitalization was entirely attributable to lithium-induced deterioration of lung function. Perhaps comparisons of mid-maximal expiratory flows, which would have been less effort-dependent and more sensitive to obstruction in small airways, would have provided a better assessment of airway dysfunction attributable to lithium. What can we learn from this study? Obviously, caution must be exercised in the treatment of CF patients with lithium. In addition, the possibility that lithium alters transport function of both sweat gland and airway epithelia in CF deserves careful investigation. A note of caution also may be in order. At a time when CF clinical research appears to be entering a most active and potentially productive phase, patient enrollment should be reserved for trials that have a sound scientific rationale and are most likely to provide important information. To do
Novel Mutations In Col4a3, Col4a4, And Col4a5 In Chinese Patients With Alport Syndrome

Jian-Hong Liu,Xiu-Xiu Wei,Ang Li,Ying-Xia Cui,Xin-Yi Xia,Wei-Song Qin,Ming-Chao Zhang,Er-Zhi Gao,Jun Sun,Chun-Lin Gao,Feng-Xia Liu,Qiu-Yue Wu,Wei-Wei Li,Asan,Zhi-Hong Liu,Xiao-Jun Li

DOI: https://doi.org/10.1371/journal.pone.0177685

IF: 3.7

2017-01-01

PLoS ONE

Abstract:Alport syndrome (AS) is a clinically and genetically heterogeneous, progressive nephropathy caused by mutations in COL4A3, COL4A4, and COL4A5, which encode type IV collagen. The large sizes of these genes and the absence of mutation hot spots have complicated mutational analysis by routine polymerase chain reaction (PCR)-based approaches. Here, in order to design a rapid and effective method for the genetic diagnosis of AS, we developed a strategy by utilizing targeted capture associated with next-generation sequencing (NGS) to analyze COL4A3, COL4A4, and COL4A5 simultaneously in 20 AS patients. All the coding exons and flanking sequences of COL4A3, COL4A4, and COL4A5 from the probands were captured followed by HiSeq 2500 sequencing. Candidate mutations were validated by classic Sanger sequencing and quantitative (q) PCR. Sixteen patients (16/20, 75%) showed X-linked inheritance, and four patients (4/20, 20%) showed autosomal recessive inheritance. None of the individuals had autosomal-dominant AS. Fifteen novel mutations, 6 known mutations, and 2 novel fragment deletions were detected by targeted capture and NGS. Of these novel mutations, 12, 3, and 2 mutations were detected in COL4A5, COL4A4, and COL4A3, respectively. A comparison of the clinical manifestations caused by different types of mutations in COL4A5 suggested that nonsense mutations and glycine substitution by an acidic amino acid are more severe than the other missense mutations. Pathogenic mutations were detected in 20 patients. These novel mutations can expand the genotypic spectrum of AS. Our results demonstrated that targeted capture and NGS technology are effective in the genetic diagnosis of AS.
A novel COL4A5 splicing mutation causes alport syndrome in a Chinese family

Suyun Chen,Guangbiao Xu,Zhixin Zhao,Juping Du,Bo Shen,Chunping Li

DOI: https://doi.org/10.1186/s12920-024-01878-8

2024-04-27

BMC Medical Genomics

Abstract:Alport syndrome (AS) is characterised by haematuria, proteinuria, a gradual decline in kidney function, hearing loss, and eye abnormalities. The disease is caused by mutations in COL4An ( n = 3, 4, 5) that encodes 3–5 chains of type IV collagen in the glomerular basement membrane. AS has three genetic models: X-linked, autosomal recessive, and autosomal dominant. The most common type of AS is X-linked AS, which is caused by COL4A5 .

genetics & heredity
Trigenic COL4A3/COL4A4/COL4A5 pathogenic variants in Alport syndrome: a case report

Dipti Rao,Rutger Maas,Marlies Cornelissen,Jack Wetzels,Michel van Geel

DOI: https://doi.org/10.1159/000538587

2024-03-28

Nephron

Abstract:Alport syndrome (AS) is a hereditary kidney disorder of type IV collagen caused by pathogenic variants in the COL4A3, COL4A4 and COL4A5 genes. Previously several cases of digenic AS, caused by two pathogenic variants in two of the three COL4A genes, have been reported. Patients with digenic AS may present with a more severe phenotype compared to patients with single variants, depending on the percentage affected type IV trimeric collagen chain. We report a newly discovered case of trigenic AS. A 52-year-old female presented with hematuria at the age of 24 years and developed hypertension by the age of 30. Over the years she developed chronic kidney disease; the most recent eGFR was 44ml/min/1.73m2. She has symmetric high-tone sensorineural hearing loss. Full genetic analysis revealed a heterozygous pathogenic variant c.2691del in COL4A3, a heterozygous pathogenic variant c.1663dup in COL4A4, and a complete heterozygous deletion of COL4A5. We describe the first patient with AS caused by pathogenic variants in all three COL4A genes, designated trigenic AS. This case report emphasizes the importance of examining all three COL4A genes, even in patients with a mild Alport phenotype, for optimal follow-up of the patient and adequate genetic counseling of family members.

urology & nephrology
Synergistic Toxicity of Compound Heterozygous Mutations in the COL4A3 Gene Causes End-Stage Renal Disease in A Large Family of Alport Syndrome

Longxin Xie,Yuxi Ding,Ying Qiu,Yi Shi

DOI: https://doi.org/10.1016/j.gene.2024.149132

IF: 3.913

2024-01-01

Gene

Abstract:Alport syndrome (AS) is a genetic disorder characterized by kidney disease and hearing/vision abnormalities, resulting from mutations in the COL4A3, COL4A4, or COL4A5 genes. While numerous mutations have been identified in AS cases, the precise molecular mechanisms, particularly for compound mutations, remain under investigation. This study investigated the molecular mechanisms of AS in a proband with end-stage kidney disease (ESKD) using whole exome sequencing, which identified two compound heterozygous COL4A3 missense mutations: NM_000091.5:c.1354G > A (p.G452R) and NM_000091.5:c.4793 T > G (p.L1598R). Sixteen family members of the proband were genotyped, and further analyses, including in silico structural prediction, molecular docking, and in vitro co-immunoprecipitation assays, revealed that the p.G452R mutation disrupted the collagen triple helical structure, associated with hematuria in carriers, while the p.L1598R mutation interfered with the interaction between the NC1 domains of COL4A3 and COL4A4 proteins, crucial for collagen trimerization. These findings demonstrate a synergistic loss-of-function effect of the two mutations, contributing to the AS pathogenesis in the proband, and emphasize the importance of genetic screening and personalized treatment strategies for AS.
A Novel Loss-of-Function Variant in COL4A3 in a Consanguineous Moroccan Family Displaying the Alport Syndrome with Variable Clinical Expression

Oumayma Taroua,Omar Askander,Hakima Rhou,Ahmed Bouhouche

DOI: https://doi.org/10.1159/000540122

2024-07-24

Molecular Syndromology

Abstract:Introduction: Alport syndrome (AS) is a rare genetic disorder characterized by abnormalities in the kidneys, ears, and eyes. Its clinical presentation typically manifests in childhood or adolescence and varies widely among affected individuals, ranging from isolated hematuria to end-stage renal disease. The genetic causes of AS primarily involve mutations in the genes encoding type IV collagen COL4A3 , COL4A4 , and COL4A5 , which play essential roles in maintaining the structural integrity of the glomerular basement membrane in the kidney, the cochlea, and the retina. They can be transmitted in autosomal dominant, autosomal recessive, and X-linked recessive. Case Presentation: Here we report a Moroccan consanguineous family with an 18-year-old girl who presented with advanced renal failure and microscopic hematuria. Her audiometry revealed hearing impairment. Urinalysis performed in all the asymptomatic family members showed microscopic hematuria in the mother and younger sister, while computed tomography excluded a urologic cause. Using next-generation sequencing analysis, we identified in the proband a nonsense homozygous variant in the COL4A3 gene (c.4114C>T, p.Gln1372Ter) that was never reported in the literature, and which is considered pathogenic according to the ACMG classification. Segregation analysis in the family showed that the parents were heterozygous like the elder brother, whereas the younger sister was mutated homozygous, and the other brother was homozygous normal. Conclusion: We report a novel nonsense pathogenic variant in COL4A3 that expends the allelic spectrum in AS. Clinical exploration and genetic testing of all the family members revealed intrafamilial clinical variability, suggesting a pseudo-dominant inheritance and a reduced penetrance.

genetics & heredity
A Pedigree with COL4A5 Mutation Presenting with Alport Syndrome and Focal Segmental Glomerulosclerosis Lesions: a Case Report.

Honghong Zou,Li Zhu,Rong Xu,Sufang Shi,Suxia Wang,Fude Zhou,Hong Zhang,Minghui Zhao

2022-01-01

Abstract:Alport syndrome (AS) is a heterogeneous hereditary nephropathy which can be caused by the COL4A3/COL4A4/COL4A5 gene. Patients with AS present with many phenotypes associated with kidney defects, and commonly develop secondary focal segmental glomerulosclerosis (FSGS) late in the course of AS. Evidence supports the pathogenic role of COL4A3/COL4A4/COL4A5 mutations in FSGS. We report a familial hematuria pedigree with two members that have AS and FSGS, respectively. The proband presented with microhematuria, proteinuria, renal dysfunction and sensorineural hearing loss. Pathological examination of his renal biopsy samples revealed FSGS lesions and massive foam cells by light microscopy, irregular GBM, and focal podocyte foot process effacement under electron microscopy, as well as negative α5 (IV) staining by immunofluorescence detection so he was diagnosed as AS. The proband's younger brother had only renal manifestations without obvious extrarenal lesions. Light microscopy examination of renal biopsy samples showed only FSGS lesion without foam cells. Electron microscopy and α5 (IV) staining were not performed and he was diagnosed with FSGS. Using whole-exome sequencing, we identified a novel COL4A5 mutation (c.4456G>A:p.G1486S) in this pedigree, which affected two males (the proband and his brother) and three female family members. The three female family members were heterozygous or the COL4A5 mutation and only presented with microhematuria. Our findings suggest importance of electron microscopy analysis and COL4A3/COL4A4/COL4A5 mutation screening in patients with FSGS lesions under light microscopy.
Genetic diagnosis of Alport syndrome in 16 Chinese families

Tangli Xiao,Jun Zhang,Li Liu,Bo Zhang

DOI: https://doi.org/10.1002/mgg3.2406

2024-03-05

Molecular Genetics & Genomic Medicine

Abstract:Background Alport syndrome (AS) is a genetically heterogeneous disorder resulting from mutations in the collagen IV genes COL4A3, COL4A4, and COL4A5. The genetic diagnosis of AS is very important to make precise diagnosis and achieve optimal outcomes. Methods In this study, 16 Chinese families with suspected AS were recruited after pedigree analysis, and the clinical presentations were analyzed by a nephrologist. The genetic diagnosis was performed by whole‐exome sequencing (WES) and the disease‐causing variants were confirmed by Sanger sequencing. Results The cohort of probands included seven men and nine women, with a mean age of 19.9 years. Pathological analysis showed slight‐to‐moderate mesangial proliferation, and thin basement membrane was the main findings. Pathogenic variants were revealed by WES in each family, and the co‐segregation with renal presentation was confirmed by PCR. In addition, RT‐PCR analysis showed that the intronic variant led to aberrant splicing. Conclusion Our findings expand the spectrum of AS gene variation, which will inform genetic diagnosis and add to the theoretical basis for the prevention of AS.

genetics & heredity
Generating information from electronic patient records in general practice: a description of clinical care and gender inequalities in coronary heart disease using data from over two million patient records.

P. Horsfield,S. Teasdale

DOI: https://doi.org/10.14236/JHI.V11I3.562

Informatics in Primary Care

Abstract:OBJECTIVES To describe the epidemiology of coronary heart disease (CHD) in England and the activity of primary healthcare teams in managing patients with CHD, and also to demonstrate the utility of computerised patient records in providing access to epidemiological data and data reflecting healthcare activity. DESIGN A descriptive survey of CHD and related clinical data, recorded using computerised clinical records, entered by primary healthcare teams. Aspects reported include prevalence of CHD, together with additional data reflecting clinical monitoring activity, therapeutic interventions and comorbidity in patients affected by CHD. SETTING 317 general practices in 23 English primary care trusts (PCTs). DATA ACQUISITION MIQUEST was used to interrogate 2 252 274 computerised patient records. Data were extracted in the form of sex and age aggregated counts of patients meeting a range of extraction criteria. RESULTS The observed crude prevalence of CHD is 40.3 per 1000 (males 46.6, females 34.2). A variety of findings are presented relating to the treatment, monitoring and comorbidities of CHD. Significant and systematic gender inequalities are demonstrated to exist in the monitoring and treatment of CHD. CONCLUSIONS Extraction of data from computerised patient records is a valuable and practicable method of generating information to inform clinicians and National Health Service (NHS) organisations. Systematic gender disparities exist in the care delivered to patients with CHD.
Analyzing three pedigrees in X-linked Alport syndrome with the presentation of nephrotic syndrome

Jian-Hui Zhang,Jie Liu,Dan-Dan Ruan,Qian Chen,Jie Yang,Min Wu,Hong-Ping Yu,Li-Sheng Liao,Xiao-Ling Zheng,Jie-Wei Luo,Li Zhang

DOI: https://doi.org/10.3389/fgene.2024.1419154

2024-08-09

Abstract:Background: Alport syndrome (AS) is a common cause of end-stage renal disease (ESRD) with various clinical symptoms and incomplete manifestation. Patients with AS and other renal disorders are often misdiagnosed. This study reported three X-linked dominant Alport syndrome (XLAS) pedigrees with nephrotic syndrome (NS) as the predominant phenotype and analyzed COL4A5 gene alterations. Methods: Three Han Chinese XLAS pedigrees were recruited, and clinical phenotypes were obtained. The pre-certified individuals' peripheral blood DNA was taken, and whole-genome next-generation sequencing (NGS) was performed for candidate genes and mutation screening, followed by NGS or Sanger sequencing of suspected mutant types in participating family members. Results: Both probands A and B were diagnosed with NS through biochemical tests, and X-linked Alport syndrome-associated renal injury was diagnosed by renal biopsy. The biopsy revealed focal foamy cells in the renal interstitium, tearing and delamination changes in the glomerular basement membrane, and negative α3 and α5 chains of type IV collagen. Proband C, who was earlier diagnosed with NS, has now advanced to ESRD, along with his mother and proband A's mother. Genetic sequencing of all three pedigrees identified three mutations, namely, c.5020C>T, c.4435_4445del, and c.1584_1587+6del in the X-linked dominant gene COL4A5 (NM_000495.5). These mutations lead to the production of shortened proteins, potentially impacting the function of COL4A5 and causing pathogenic effects. Conclusion: The novel c.4435_4445del and c.1584_1587+6del mutations not only enrich the spectrum of mutations in the COL4A5 gene but also indicate that carriers of both mutation sites and those with mutation c.5020C>T may present NS as their primary clinical manifestation.
[Features of Clinical Phenotype and Genotype in Alport Syndrome: a Monocentric Study].

Lei Sun,Xinyu Kuang,Sheng Hao,Ping Wang,Xiaoling Niu,Guanghua Zhu,Junmei Zhou,Wenyan Huang

DOI: https://doi.org/10.3760/cma.j.issn.0578-1310.2015.02.010

2015-01-01

Abstract:OBJECTIVE:To analyze the clinical features and gene mutation of Chinese children with Alport syndrome(AS).METHOD:From May 2011 to May 2014, clinical and pathological information gathered from 25 patients was retrospectively analyzed. COL4A5, COL4A4 and COL4A3 genes were analyzed using next-generation sequencing in these patients, and gene mutations of related family members were identified by Sanger method.RESULT:Of these 25 cases, 19(76%) had X-linked Alport syndromes (XL-AS), 6 had autosomal recessive Alport syndromes (AR-AS). Twenty five patients had an onset of hematuria and proteinuria and in 8 cases the disease was induced by upper respiratory tract infections. Hearing loss was present in 2 of 25 (8%) cases and ocular lesions in 1 of 25 (4%). Renal pathology showed that 16 of them had minimal change disease (MCD), 8 mesangial proliferative glomerulonephritis (MsPNG), 1 focal segmental glomerulo-sclerosis (FSGS). Extensive lamination and split of glomerular basement membrane (GBM) dense layers were found in 2 (8%) of 25 patients. Twenty one of 25 patients (84%) showed abnormal renal α-chain distribution. COL4A5, COL4A4 and COL4A3 genes of 25 patients (23 families) were analyzed and 24 pathogenic mutations were identified: 18 in COL4A5, 1 in COL4A3 and 5 in COL4A4. It was observed that 13 patients inherited the mutation from the mother, 3 patients inherited from the father, 2 patients inherited 1 mutation from the mother and another mutation from the father, and 7 patients carried the novel mutations.CONCLUSION:XL is the main inherited type in AS. Most of patients showed MCD and MsPNG in renal biopsy. This research examined 24 mutations and 16 mutations were not reported previously.
A Novel Splicing Mutation Identified in a Chinese Family with X-linked Alport Syndrome Using Targeted Next-Generation Sequencing.

Chen Chen,Chaoxia Lu,Qiong Wang,Lihua Cao,Yang Luo,Xue Zhang

DOI: https://doi.org/10.1089/gtmb.2015.0248

IF: 1.736

2016-01-01

Genetic Testing and Molecular Biomarkers

Abstract:Aims: Alport syndrome (AS) is a genetically heterogeneous disorder, characterized by hematuria, progressive renal failure, sensorineural hearing loss, and ocular abnormalities caused by mutations in the COL4A3, COL4A4, and COL4A5 genes. The aim of this study was to identify underlying mutations in individuals from a Chinese family with X-linked AS. Methods: We performed targeted next-generation sequencing (NGS) to identify mutations associated with AS. The results were processed and visualized using an Integrated Genomics Viewer software. The most likely disease-causing variants were identified and confirmed by Sanger sequencing of reverse transcription-polymerase chain reaction products. Results: Visual inspection using Integrative Genomics Viewer software found that COL4A5 exon 10 was not covered by the disease panel, while coverage of exons 4, 17, 20, 21, 37, and 45 was incomplete. Sanger sequencing of these regions identified a novel splice-site mutation in intron 9 (c.547-3C>A) of the COL4A5 gene. Subsequent cDNA analysis revealed that c.547-3C>A led to skipping of exon 10, which resulted in an in-frame deletion of 21 amino acids from the 5 chain of type IV collagen. Conclusion: We determined the molecular basis of AS in a Chinese family by targeted NGS and cDNA analysis. This is the first report of the novel c.547-3C>A splicing mutation in the collagen domain of COL4A5 gene.
A Novel COL4A5 Splicing Mutation Causes Skipping of Exon 14 in a Chinese Family with Alport Syndrome

Erzhi Gao,Xi Yang,Nuo Si,Keqiang Liu,Jin-Quan Wang,Zhihong Liu

DOI: https://doi.org/10.1159/000502798

2019-01-01

Kidney Diseases

Abstract:Background: Alport syndrome (AS) is an inherited progressive renal disease caused by mutations in COL4A3, COL4A4, and COL4A5. Although mutation screening in the genes responsible for AS is typically performed, only a small proportion of patients receive genetic testing in China, and the functional consequences of multiple splicing variants in AS patients have not been investigated. Methods: A family with X-linked AS was diagnosed based on family history and pathological findings from a kidney biopsy. Targeted next-generation sequencing was used to identify the causative mutation, and a minigene assay was performed to test the influence of the mutation on splicing. Results: A c.834+2T>G in COL4A5 was identified and shown to co-segregate with AS in the family. The variant is located in the canonical splicing site and is predicted to induce aberrant splicing. Minigene assay using HEK 293T cells indicated the skipping of exon 14 in COL4A5. Conclusions: The novel COL4A5 splicing mutation identified in the current study broadened the genetic spectrum of X-linked AS and further deepened our insight of the disease’s molecular mechanism.
Alport syndrome: Expanding diagnosis and treatment

Hou-Xuan Huang,I-Jung Tsai,Larry A. Greenbaum

DOI: https://doi.org/10.1016/j.pedneo.2024.10.005

IF: 2.586

2024-11-11

Pediatrics & Neonatology

Abstract:Alport syndrome (AS) is the second common monogenic cause of end-stage kidney disease (ESKD) worldwide and is caused by defective type 4 collagen due to pathogenic variants of COL4A3, COL4A4, or COL4A5 . Type 4 collagen also exists in the eyes and ears, and thus ocular defects and hearing loss occur in AS. The understanding of AS has expanded over the past two decades due to greater availability of genetic testing and research on genotype-phenotype correlation. Patients previously diagnosed with idiopathic steroid resistant nephrotic syndrome or ESKD of unknown etiology may now be diagnosed as AS if pathogenic COL4A3-5 variants are identified. Some carriers of heterozygous COL4A3-5 variants may now be classified into females with X-linked AS or autosomal dominant AS, if there are typical pathologic changes in the glomerular basement membrane or if there is proteinuria and progression of kidney disease. Lastly, it has been recommended that renin-angiotensin-aldosterone system inhibition be started as soon as possible for selected AS patients for its long-term protective effect against kidney function deterioration. The purpose of this review is to introduce these important concepts to general pediatricians and pediatric nephrologists.

pediatrics

Free and total lipid myo-inositol concentrations decrease with age in human brain.

Case report: A novel compound heterozygous variant in the COL4A3 gene was identified in a patient with autosomal recessive Alport syndrome

Novel Digenic Variants in COL4A4 and COL4A5 Causing X-Linked Alport Syndrome: A Case Report

Identification of a Novel COL4A5 Mutation in the Proband Initially Diagnosed As IgAN from a Chinese Family with X-linked Alport Syndrome.

A Novel COL4A5 Pathogenic Variant Joins the Dots in a Family with a Synchronous Diagnosis of Alport Syndrome and Polycystic Kidney Disease

A Novel Mutation of COL4A3 Presents a Different Contribution to Alport Syndrome and Thin Basement Membrane Nephropathy

Autosomal Dominant Alport Syndrome Caused by a Novel COL4A4 Gene Mutation:a Case Report and Literature Review

Lithium, clinical research, and cystic fibrosis

Novel Mutations In Col4a3, Col4a4, And Col4a5 In Chinese Patients With Alport Syndrome

A novel COL4A5 splicing mutation causes alport syndrome in a Chinese family

Trigenic COL4A3/COL4A4/COL4A5 pathogenic variants in Alport syndrome: a case report

Synergistic Toxicity of Compound Heterozygous Mutations in the COL4A3 Gene Causes End-Stage Renal Disease in A Large Family of Alport Syndrome

A Novel Loss-of-Function Variant in COL4A3 in a Consanguineous Moroccan Family Displaying the Alport Syndrome with Variable Clinical Expression

A Pedigree with COL4A5 Mutation Presenting with Alport Syndrome and Focal Segmental Glomerulosclerosis Lesions: a Case Report.

Genetic diagnosis of Alport syndrome in 16 Chinese families

Generating information from electronic patient records in general practice: a description of clinical care and gender inequalities in coronary heart disease using data from over two million patient records.

Analyzing three pedigrees in X-linked Alport syndrome with the presentation of nephrotic syndrome

[Features of Clinical Phenotype and Genotype in Alport Syndrome: a Monocentric Study].

A Novel Splicing Mutation Identified in a Chinese Family with X-linked Alport Syndrome Using Targeted Next-Generation Sequencing.

A Novel COL4A5 Splicing Mutation Causes Skipping of Exon 14 in a Chinese Family with Alport Syndrome

Alport syndrome: Expanding diagnosis and treatment